Oppenheimer & Co. Inc. Has $6.83 Million Position in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Oppenheimer & Co. Inc. cut its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 10.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,852 shares of the exchange traded fund’s stock after selling 9,216 shares during the period. Oppenheimer & Co. Inc. owned about 0.10% of SPDR S&P Biotech ETF worth $6,831,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Hartline Investment Corp raised its stake in shares of SPDR S&P Biotech ETF by 2.0% during the third quarter. Hartline Investment Corp now owns 5,502 shares of the exchange traded fund’s stock valued at $544,000 after acquiring an additional 106 shares during the last quarter. Addison Advisors LLC raised its position in SPDR S&P Biotech ETF by 27.4% during the 4th quarter. Addison Advisors LLC now owns 535 shares of the exchange traded fund’s stock worth $48,000 after purchasing an additional 115 shares during the last quarter. Signature Estate & Investment Advisors LLC raised its position in SPDR S&P Biotech ETF by 5.7% during the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 2,336 shares of the exchange traded fund’s stock worth $231,000 after purchasing an additional 125 shares during the last quarter. Graypoint LLC lifted its holdings in SPDR S&P Biotech ETF by 5.6% during the 3rd quarter. Graypoint LLC now owns 2,738 shares of the exchange traded fund’s stock worth $271,000 after buying an additional 146 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of SPDR S&P Biotech ETF by 0.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,873 shares of the exchange traded fund’s stock valued at $2,373,000 after buying an additional 148 shares during the last quarter.

SPDR S&P Biotech ETF Trading Down 1.3 %

Shares of XBI stock opened at $87.10 on Friday. The stock has a 50-day moving average of $91.06 and a 200-day moving average of $95.80. The stock has a market cap of $5.74 billion, a price-to-earnings ratio of 11.47 and a beta of 0.93. SPDR S&P Biotech ETF has a 1-year low of $81.14 and a 1-year high of $105.47.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.